Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Orkin, Chloe"" wg kryterium: Autor


Tytuł :
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Autorzy :
Orkin, Chloe
Pokaż więcej
Źródło :
In The Lancet HIV June 2020 7(6):e389-e400
Czasopismo naukowe
Tytuł :
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
Autorzy :
Iwuji, Collins C.Aff1, Aff2
Churchill, Duncan
Bremner, Stephen
Perry, Nicky
To, Ye
Lambert, Debbie
Bruce, Chloe
Waters, Laura
Orkin, ChloeAff6, Aff7
Geretti, Anna Maria
Pokaż więcej
Źródło :
BMC Infectious Diseases. 20(1)
Czasopismo naukowe
Tytuł :
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Autorzy :
De Wit, S.
Pokaż więcej
Źródło :
In Antiviral Research October 2019 170
Czasopismo naukowe
Tytuł :
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
Autorzy :
Aboud, Michael
Pokaż więcej
Źródło :
In The Lancet HIV September 2019 6(9):e576-e587
Czasopismo naukowe
Tytuł :
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Autorzy :
Cassetti, Lidia
David, Daniel
Figueras, Laura
Losso, Marcelo
Lopardo, Gustavo
Lupo, Sergio
Porteiro, Norma
Sánchez, Marisa
Bloch, Mark
Cooper, David
Finlayson, Robert
Kelleher, Anthony
Koh, Kenneth
Lewis, David
McMahon, James
Moore, Richard
Roth, Norman
Shields, Matthew
De Wit, Stephane
Florence, Eric
Goffard, Jean-Christophe
Demeester, Remy
Lacor, Patrick
Vandercam, Bernard
Vandekerckhove, Linos
Angel, Jonathan
Baril, Jean-Guy
Conway, Brian
De Pokomandy, Alexandra
Szabo, Jason
Walmsley, Sharon
Bouchaud, Olivier
Chidiac, Christian
Delobel, Pierre
Goujard, Cecile
Katlama, Christine
Molina, Jean-Michel
Pialoux, Gilles
Philibert, Patrick
Bogner, Johannes
Esser, Stefan
Krznaric, Ivanka
Lehmann, Clara
Spinner, Christoph
Stellbrink, Hans-Jurgen
Stephan, Christoph
Stoehr, Albrecht
Barchi, Enrico
Caramello, Pietro
Castelli, Francesco
Cattelan, Anna Maria
D'Arminio Monforte, Antonella
Di Biagio, Antonio
Di Perri, Giovanni
Gori, Andrea
Maggiolo, Franco
Menzaghi, Barbara
Migliorino, Guglielmo
Mussini, Cristina
Penco, Giovanni
Puoti, Massimo
Rizzardini, Giuliano
Gulminetti, Roberto
Lazzarin, Adriano
Quirino, Tiziano
Sighinolfi, Laura
Viale, Pierluigi
Amaya Tapia, Gerardo
Andrade Villanueva, Jaime
Granados Reyes, Enrique R
Perez Rios, Alma
Santoscoy Gomez, Mario
Den Hollander, Jan
Rijnders, Bart
Hidalgo, José A
Hercilla Vasquez, Luis
Illescas, Luis
Olczak, Anita
Mansinho, Kamal
Correia Pacheco, Patricia Paula
Teófilo, Eugénio
Saraiva da Cunha, Jose
Sarmento e Castro, Rui
Serrão, Rosário
Arbune, Manuela
Jianu, Cristian
Oprea, Anca
Preotescu, Liliana
Prisacariu, Liviu-Jany
Belonosova, Elena
Borodkina, Olga
Chernova, Oxana
Gankina, Natalia
Kizhlo, Svetlana
Kulagin, Valeriy
Kurina, Nadezhda
Nagimova, Firaya
Pokrovsky, Vadim
Ryamova, Elena
Voronin, Evgeny
Yakovlev, Alexey
Kaplan, Richard
Lee, Sun Hee
Kim, Shin-Woo
Kim, Sang-Il
Kim, Woo Joo
Antela Lopez, Antonio
Casado Osorio, Jose L
Castaño Carracedo, Manuel A
De Los Santos Gil, Ignacio
Estrada Perez, Vicente
Falco Ferrer, Vicenç
Force, Luis
Galinda Puerto, Maria Jose
Garcia Deltoro, Miguel
Gatell, Josep M
Goenaga Sanchez, Miguel A
González Cordón, Ana
Knobel, Hernando
Lopez Bernaldo de Quiros, Juan Carlos
Losa Garcia, Juan E
Masia, Mar
Montero-Alsonso, Marta
Ocampo Hermida, Antonio
Pasquau Liaño, Juan
Portilla Sogorb, Joaquin
Pulido Ortega, Federico
Rivera Roman, Antonio
Santos Fernandez, Jose Ramon
Torres Perea, Rafael
Troya Garcia, Jesus
Viciana Fernandez, Pompeyo
Calmy, Alexandra
Hauser, Christoph
Fehr, Jan
Cheng, Shu-Hsing
Ko, Wen-Chien
Lin, Hsi-Hsun
Lu, Po-Liang
Tseng, Yu-Ting
Wang, Ning-Chi
Wong, Wing-Wai
Yang, Chia-Jui
Arduino, Roberto
Benson, Paul
Berhe, Mezgebe
Bredeek, Fritz
Brinson, Cynthia
Campbell, Thomas
Crofoot, Gordon
Cunningham, Douglas
DeJesus, Edwin
Dretler, Robin
Eron, Joseph
Fife, Kenneth
Fichtenbaum, Carl
Flamm, Jason
Goldstein, Deborah
Gupta, Samir
Hagins, Debbie
Hoffman-Terry, Margaret
Jayaweera, Dushyantha
Kinder, Clifford
Klein, Daniel
McDonald, Cheryl
Mills, Anthony
Nahass, Ronald
Osiyemi, Olayemi
Overton, Edgar
Parks, David
Prelutsky, David
Ramgopal, Moti
Schrader, Shannon
Sha, Beverly
Simon, Gary
Sims, James
Skiest, Daniel
Slim, Jihad
Tashima, Karen
Thedinger, Blair
Gazzard, Brian
Fox, Julie
Johnson, Margaret
Kegg, Stephen
Khoo, Saye
Mazhude, Charles
Orkin, Chloe
Schembri, Gabriel
Ustianowski, Andrew
Cahn, Pedro
Pokaż więcej
Źródło :
In The Lancet 12-18 January 2019 393(10167):143-155
Czasopismo naukowe
Tytuł :
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
Autorzy :
Huhn, Gregory D.
Eron, Joseph J.
Girard, Pierre-Marie
Orkin, Chloe
Molina, Jean-Michel
DeJesus, Edwin
Petrovic, Romana
Luo, Donghan
Van Landuyt, Erika
Lathouwers, Erkki
Nettles, Richard E.
Brown, Kimberley
Wong, Eric Y.
Pokaż więcej
Źródło :
AIDS Research and Therapy. 16(1)
Czasopismo naukowe
Tytuł :
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Autorzy :
Ajana, F
Arribas, JR
Bailey, J
Benson, P
Berenguer, J
Bhatti, L
Blaxhult, A
Brar, I
Bredeek, UF
Brinson, C
Brunetta, J
Casado, J
Clarke, A
Conway, B
Cotte, L
Crofoot, G
Cunningham, D
de Vente, J
De Wit, S
DeJesus, E
Dietz, C
Dretler, R
Eron, J
Fehr, J
Felizarta, F
Fichtenbaum, C
Flamholc, L
Florence, E
Galindo, MJ
Gallant, J
Gasiorowski, J
Gatell, JM
Gathe, J
Gazzard, BG
Girard, P-M
Gisslèn, M
Gutierrez, F
Gutierrez, MDM
Hagins, D
Halota, W
Henn, S
Henry, WK
Horban, A
Huhn, G
Iribarren, JA
Jain, M
Johnson, MA
Katlama, C
Klein, M
Knobel, H
Lucasti, C
Martorell, C
McDonald, C
Mills, A
Molina, J-M
Morales-Ramirez, J
Mounzer, K
Moutschen, M
Murphy, D
Nahass, R
Negredo, E
Olivet, H
Orkin, C
Osiyemi, O
Perez-Valero, I
Piekarska, A
Pineda, JA
Podzamczer, D
Poizot-Martin, I
Portilla Sogorb, J
Post, F
Prelutsky, D
Pulido, F
Rachlis, A
Raffi, F
Ramgopal, M
Rashbaum, B
Rauch, A
Rey, D
Reynes, J
Ricart, C
Richmond, G
Rivero, A
Ruane, P
Gil, I Santos
Scarsella, A
Scribner, A
Shafran, S
Shalit, P
Shamblaw, D
Slim, J
Stoeckle, M
Tashima, K
Teicher, E
Thalme, A
Ustianowski, A
Van Wijngaerden, E
Vandekerckhove, L
Vandercam, B
Voskuhl, G
Walmsley, S
Ward, D
Waters, L
Wilkin, A
Witor, A
Yazdanpanah, Y
Orkin, Chloe
Pokaż więcej
Źródło :
In The Lancet HIV January 2018 5(1):e23-e34
Czasopismo naukowe
Tytuł :
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
Autorzy :
Cahn, Pedro Enrique
Cassetti, Lidia Isabel
Porteiro Barreira, Norma
Angel, Jonathan Benjamin
de Pokomandy, Alexandra
Harris, Marianne
Rachlis, Anita R.
Walmsley, Sharon L.
Allavena, Clotilde
Bouchaud, Oliver
Gatey, Caroline
Rami, Agathe
Casari, Salvatore
Di Perri, Giovanni
Lazzarin, Adriano
Maggiolo, Franco
Penco, Giovanni
Quirino, Tiziana
Rizzardini, Giuliano
Andrade-Villanueva, Jaime-Federico
Sierra-Madero, Juan G.
Branco, Teresa
Serrao, Rosario
Teofilo, Eugenio JR.
Melendez-Rivera, Ivan
Santiago, Lizette
Zorrilla, Carmen D.
Belonosova, Elena
Chernova, Oksana E.
Pokrovsky, Vadim
Rakhmanova, Aza Gasanovna
Tsybakova, Olga
Voronin, Eugene
Orrell, Catherine
Vally, Tasneem
Farisani, Livhuwani ML.
Sebopa, Boitumelo Lucrecia
Barros, Carlos Aguado
Cano Sánchez, Alfredo
Castaño, Manuel
Falcó Ferrer, Vicens
González García, Juan J.
Hernandez-Quero, Jose
Negredo Puigmal, Eugenia
Pérez Elías, María Jesús
Podzamczer Palter, Daniel
Portilla, Joaquin Sogorb
Viciana Fernández, Pompeyo
Manosuthi, Weerawat
Ruxrungtham, Kiat
Dockrell, David H.
Hay, Phillip E.
Johnson, Margaret A.
Mackie, Nicola E.
Orkin, Chloe M.
Taylor, Steve
Bhatti, Laveeza
Brar, Indira
Brennan, Robert Owen
Cade, Jerry L.
Casanas, Beata
Casey, Kathleen
Cunningham, Douglas
DeJesus, Edwin
Dietz, Craig
Dretler, Robin Henry
Eron, Jr. Joseph J.
Felizarta, Franco Antoni B.
Fife, Kenneth H.
Hagins, Debbie P.
Hoffman-Terry, Margaret
Jain, Mamta
Johnson, Marc Alexander
Kinder, Clifford A.
Kumar, Princy N.
Lewis, Jr. Stanley T.
McDonald, Cheryl Kay
Meza, Armando D.
Mounzer, Karam C.
Newman, Cheryl L.
Osiyemi, Olayemi O.
Poblete, Ronald
Presti, Rachel M.
Ramgopal, Moti
Rosenstock, Joel
Samuel, Rafik
Sandkovsky, Uriel Sebastian
Shon, Alyssa So Young
Skiest, Daniel J.
Sloan, Louis M.
Small, Catherine B.
Tebas, Pablo
Van Dam, Cornelius N.
Orrell, Catherine
Pokaż więcej
Źródło :
In The Lancet HIV December 2017 4(12):e536-e546
Czasopismo naukowe
Tytuł :
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Autorzy :
Gallant, Joel
Pokaż więcej
Źródło :
In The Lancet 4-10 November 2017 390(10107):2063-2072
Czasopismo naukowe
Tytuł :
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Autorzy :
Orkin, Chloe
Pokaż więcej
Źródło :
In The Lancet HIV May 2017 4(5):e195-e204
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies